Prevalence and Incidence of Dermatomyositis
Prevalance of Dermatomyositis:
13,462 people with polymyositis/dermatomyositis in the USA 1996 1 ... see also overview of Dermatomyositis.
Prevalance Rate:
approx 1 in 20,205 or 0.00% or 13,461 people in USA [Source statistic for calcuation: "13,462 people with polymyositis/dermatomyositis in the USA 1996 1" -- see also general information about data sources]
Dermatomyositis: Rare Disease
Dermatomyositis is listed as a "rare disease" by the Office of
Rare Diseases (ORD) of the National Institutes of Health
(NIH). This means that Dermatomyositis, or a subtype of Dermatomyositis,
affects less than 200,000 people in the US population.
Ophanet, who are a consortium of European partners,
currently defines a condition rare when if affects 1 person per 2,000.
They list Dermatomyositis as a "rare disease".
More information about Dermatomyositis is available from Orphanet
Dermatomyositis Prevalence: Book Excerpts
More Statistics about Dermatomyositis:
Hospitalization statistics
All statistics for Dermatomyositis
Prevalence/Incidence of Dermatomyositis: Online Medical Books
16 MEDICAL BOOKS ONLINE!
Review excerpts from medical books online, free, without registration,
for more information about the prevalence and/or incidence of Dermatomyositis.
Polymyositis and dermatomyositis:
Causes and incidence
(Professional Guide to Diseases (Eighth Edition))
Although the cause of polymyositis remains puzzling, researchers believe that it may result from an autoimmune reaction. Presumably, the patient’s T cells inappropriately recognize muscle fiber antigens as foreign and attack muscle tissue, causing diffuse or focal muscle fiber degeneration. (Regeneration of new muscle cells then follows, producing remission.) Polymyositis and dermatomyositis may be associated with other disorders, such as allergic reactions; systemic lupus erythematosus (SLE); scleroderma; rheumatoid arthritis; Sjögren’s syndrome; carcinomas of the lung, breast, or other organs; systemic viral infection; or d-penicillamine administration.
Annual incidence is 1 in 100,000 people.
» READ BOOK EXCERPT ONLINE »
Source: Professional Guide to Diseases (Eighth Edition), 2005
Dermatomyositis/Polymyositis:
Dermatomyositis/Polymyositis - epidemiology
(The 5-Minute Pediatric Consult)
- The average age of onset is 7 years.
- Overall male/female ratio is 1:1.7; however, equal in children <10 years of age
Dermatomyositis/Polymyositis - incidence
1:200,000
>
» READ BOOK EXCERPT ONLINE »
Source: The 5-Minute Pediatric Consult, 2008
About prevalence and incidence statistics:
The term 'prevalence' of Dermatomyositis usually refers to the estimated population
of people who are managing Dermatomyositis at any given time.
The term 'incidence' of Dermatomyositis refers to the annual diagnosis rate,
or the number of new cases of Dermatomyositis diagnosed each year.
Hence, these two statistics types can differ:
a short-lived disease like flu can have high annual incidence but low prevalence,
but a life-long disease like diabetes has a low annual incidence but high prevalence.
For more information see about prevalence and incidence statistics.
Every parent knows at least one thing about keeping children clean: it's not easy. But cleanliness is about more getting rid of smudges and...
Eczema may not be a life-threatening condition, but it is life altering. Learn how people can manage eczema by avoiding triggers and treating...
Alleviating the symptoms of eczema is important for people who suffer with this skin condition. Steroid therapies have been a great help, but their...
There are a variety of different treatments that can help control eczema. The therapies can come as creams, ointments or even as pills. However, not...
See full list of 5 related videos
» Next page: Videos related to Dermatomyositis
Rate This Website
What do you think about the features of this website?
Take our user survey and have your say:
Website User Survey
Medical Tools & Articles:
Next articles:
Tools & Services:
Medical Articles:
Forums & Message Boards
- Ask or answer a question at the Boards: